Project

Back to overview

Understanding and improving the selective molecular targeting of neovasculature

English title Understanding and improving the selective molecular targeting of neovasculature
Applicant Neri Dario
Number 105919
Funding scheme Project funding (Div. I-III)
Research institution Institut für Pharmazeutische Wissenschaften ETH Zürich
Institution of higher education ETH Zurich - ETHZ
Main discipline Experimental Cancer Research
Start/End 01.10.2004 - 30.09.2009
Approved amount 798'334.00
Show all

Keywords (6)

angeogenesis-related diseases; human antibodies; protein engineering; biopharmaceuticals; cancer; oncofetal fibronectin

Lay Summary (English)

Lead
Lay summary
Seven derivatives of vascular targeting antibodies developed in the Group Neri (four immunocytokines and three radiolabeled antibodies) are currently being investigated in Phase I and Phase II clinical trials, in collaboration with pharmaceutical companies. In order to capitalize on the experience gained over the last thirteen years of research in vascular tumor targeting, within the frame of this SNF Grant we have mainly focused on: (i) the isolation of novel human monoclonal antibodies specific to newly identified putative markers of angiogenesis (ii) the development and in vivo testing of novel vascular targeting immunocytokines, alone and in combination with other drugs, for applications in oncology or in other angiogenesis-related diseases.
Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants

Employees

Associated projects

Number Title Start Funding scheme
126988 Understanding and improving the selective molecular targeting of tumor neo-vasculature 01.10.2009 Project funding (Div. I-III)
64912 Understanding and improving the selective targeting of angiogene-sis 01.10.2001 Project funding (Div. I-III)

-